Glioblastoma and other primary brain malignancies in adults: a review
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
Network pharmacology: curing causal mechanisms instead of treating symptoms
For complex diseases, most drugs are highly ineffective, and the success rate of drug
discovery is in constant decline. While low quality, reproducibility issues, and translational …
discovery is in constant decline. While low quality, reproducibility issues, and translational …
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
M Lim, M Weller, A Idbaih, J Steinbach… - Neuro …, 2022 - academic.oup.com
Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase …
A Omuro, AA Brandes, AF Carpentier, A Idbaih… - Neuro …, 2023 - academic.oup.com
Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
A major rate-limiting step in develo** more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …
inadequate understanding of the cellular complexity and the molecular heterogeneity of …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
[HTML][HTML] EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
M Weller, M van den Bent, M Preusser… - Nature reviews Clinical …, 2021 - nature.com
In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
Glioma progression is shaped by genetic evolution and microenvironment interactions
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
[HTML][HTML] Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma
The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-
intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. Here …
intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. Here …